Posted on 6/27/2017 11:00 AM
In the United States, the number of patients with Alzheimer’s disease is projected to increase from the current prevalence of around 5.5 million to around 14 million in 2050. These sobering numbers reflect...
Posted on 6/22/2017 9:50 AM
On June 21st, 2017, MMS employees worldwide showed their support for The Longest Day, part of the June Alzheimer’s & Brain Health Awareness Month...
Posted on 6/13/2017 3:39 PM
The first Alzheimer's Association grants were awarded in 1982 and included a study drug targeting the communication network in the brain by working to slow down the process that breaks these connections. Today...
Posted on 6/1/2017 2:49 PM
FDA and EMA are requiring eCTD submissions for many application types in the next year. See the table...
Posted on 5/25/2017 1:26 PM
Another significant advancement in clinical trial transparency was announced on May 18. In a joint statement released on the WHO website, 12 of the world’s largest medical research funding agencies and international organizations pledged...
Posted on 10/12/2016 11:16 AM
On Saturday, September 24th, a few MMS colleagues and I participated in the walk for St. Jude to raise funds for children with cancer and their families. This was part of an MMS volunteer opportunity organized and supported through the MMS Volunteer Committee. St. Jude has an amazing mission...
Posted on 10/10/2016 12:28 PM
MMS Senior Programming Manager Chris Hurley will be attending the PhUSE Annual Conference in Barcelona this week to present a standardized approach to de-identification in the field of clinical data anonymization and transparency.
Posted on 9/28/2016 2:48 PM
Releasing the details and results of clinical trials to the public has long been a critical ethical issue facing the pharmaceutical industry. How much information should be disclosed? How do companies developing new products protect sensitive details? What is our obligation to trial participants, the scientific community, and the world in general? Read more to find out...